Biodesix (BDSX) Competitors

Exagen (NASDAQ:XGN) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

Do institutionals & insiders hold more shares of XGN or BDSX?

75.3% of Exagen shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 12.6% of Exagen shares are held by insiders. Comparatively, 30.1% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Which has higher valuation and earnings, XGN or BDSX?

Exagen has higher earnings, but lower revenue than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exagen	$55.64M	3.85	-$15.11M	-$0.89	-10.94
Biodesix	$71.32M	0.92	-$42.93M	-$0.29	-1.54

Do analysts recommend XGN or BDSX?

Exagen presently has a consensus price target of $11.25, suggesting a potential upside of 15.50%. Biodesix has a consensus price target of $1.75, suggesting a potential upside of 292.03%. Given Biodesix's higher probable upside, analysts plainly believe Biodesix is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exagen	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Biodesix	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Which has more volatility and risk, XGN or BDSX?

Exagen has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500.

Does the media prefer XGN or BDSX?

In the previous week, Exagen had 1 more articles in the media than Biodesix. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.87 beat Exagen's score of 1.83 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
Exagen	Very Positive
Biodesix	Very Positive

Is XGN or BDSX more profitable?

Exagen has a net margin of -28.85% compared to Biodesix's net margin of -53.66%. Exagen's return on equity of -130.38% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exagen	-28.85%	-130.38%	-34.69%
Biodesix	-53.66%	-269.67%	-43.94%

Summary

Exagen beats Biodesix on 10 of the 16 factors compared between the two stocks.